N,N'-bis(2-tert-butoxycarbonylamino-ethyl)-2-(2-carboxymethyl)-1,3-di(tert-butoxycarbonylamino)propane | 874196-33-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N'-bis(2-tert-butoxycarbonylamino-ethyl)-2-(2-carboxymethyl)-1,3-di(tert-butoxycarbonylamino)propane
• 英文别名: 4-[(2-Methylpropan-2-yl)oxycarbonyl-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]amino]-3-[[(2-methylpropan-2-yl)oxycarbonyl-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]amino]methyl]butanoic acid；4-[(2-methylpropan-2-yl)oxycarbonyl-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]amino]-3-[[(2-methylpropan-2-yl)oxycarbonyl-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]amino]methyl]butanoic acid
• CAS: 874196-33-5
• 化学式: C₂₉H₅₄N₄O₁₀
• 分子量: 618.769
• InChiKey: NPMKSZWLDISNPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  43
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  173
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2-(2-(苄氧基)乙基)丙二酸二乙酯 在 硼烷四氢呋喃络合物 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 20.0~40.0 ℃ 、241.32 kPa 条件下， 反应 193.0h， 生成 N,N'-bis(2-tert-butoxycarbonylamino-ethyl)-2-(2-carboxymethyl)-1,3-di(tert-butoxycarbonylamino)propane
  参考文献：
  名称：

  APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES

  摘要：

  本发明涉及体内凋亡的放射性药物成像。该发明提供了靶向凋亡细胞的成像剂，通过选择性结合到暴露在凋亡细胞表面的氨基磷脂磷脂醇胺（PE）。这些放射性药物包括PE结合肽的螯合物共轭物的放射金属络合物。还提供了体内成像的药物组合物、试剂盒和方法。

  公开号：

  US20130189186A1

文献信息

• IMAGING FIBROSIS
  申请人：GE Healthcare Limited

  公开号：US20150320892A1

  公开（公告）日：2015-11-12

  The present invention provides a labelled compound suitable for use as an in vivo imaging agent. The in vivo imaging agent of the invention is useful in the in vivo diagnosis and imaging of fibrosis and in particular fibrosis in the liver. Also provided by the present invention is a method for the preparation of the labelled compound of the invention and a precursor compound useful in said method and a kit useful for carrying out said method. In addition, the present invention provides a pharmaceutical composition comprising the labelled compound of the invention as well as a method of in vivo imaging using the labelled compound of the invention, preferably as the pharmaceutical composition of the invention.

  本发明提供了一种适用于体内成像剂的标记化合物。本发明的体内成像剂对于纤维化的诊断和成像，特别是肝脏纤维化的体内成像非常有用。本发明还提供了一种制备所述标记化合物的方法，以及一种在该方法中有用的前体化合物和一种用于执行该方法的工具包。此外，本发明还提供了包括所述标记化合物的制药组合物，以及使用所述标记化合物的体内成像方法，最好作为本发明的制药组合物。
• N4 CHELATOR CONJUGATES
  申请人：GE Healthcare Limited

  公开号：EP1768708B1

  公开（公告）日：2017-05-17
• US7431914B2
  申请人：——

  公开号：US7431914B2

  公开（公告）日：2008-10-07
• [EN] IMAGING FIBROSIS<br/>[FR] IMAGERIE DE FIBROSE
  申请人：GE HEALTHCARE LTD

  公开号：WO2014001538A1

  公开（公告）日：2014-01-03

  The present invention provides a labelled compound suitable for use as an in vivo imaging agent. The in vivo imaging agent of the invention is useful in the in vivo diagnosis and imaging of fibrosis and in particular fibrosis in the liver. Also provided by the present invention is a method for the preparation of the labelled compound of the invention and a precursor compound useful in said method and a kit useful for carrying out said method. In addition, the present invention provides a pharmaceutical composition comprising the labelled compound of the invention as well as a method of in vivo imaging using the labelled compound of the invention, preferably as the pharmaceutical composition of the invention.
• APOPTOSIS IMAGING AGENTS BASED ON LANTIBIOTIC PEPTIDES
  申请人：Indrevoll Bard

  公开号：US20130189186A1

  公开（公告）日：2013-07-25

  The present invention relates to radiopharmaceutical imaging in vivo of apoptosis. The invention provides imaging agents which target apoptotic cells via selective binding to the aminophospholipid phosphatidylethanolamine (PE), which is exposed on the surface of apoptotic cells. The radiopharmaceuticals comprise radiometal complexes of chelator conjugates of PE-binding peptides. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

  本发明涉及体内凋亡的放射性药物成像。该发明提供了靶向凋亡细胞的成像剂，通过选择性结合到暴露在凋亡细胞表面的氨基磷脂磷脂醇胺（PE）。这些放射性药物包括PE结合肽的螯合物共轭物的放射金属络合物。还提供了体内成像的药物组合物、试剂盒和方法。